From Molecular Structure to Alzheimer Therapy.

摘要: Clinical trials in the USA, Japan and Europe have confirmed hypothesis that a steady state increase of acetylcholine resulting from cholinesterase inhibition brain results an improvement cognitive function mild to moderate Alzheimer disease (AD) patients. During last decade, systematic effort develop pharmacological treatment for AD has resulted two drugs being registered first time USA this specific indication. Both are inhibitors (ChEI). Based on these positive results, several second generation ChEI developed. An additional effect certain is maintain at constant level during 6 months one year period as compared placebo. It possible drug slowing down deterioration. Comparison clinical effects 5 demonstrates rather similar magnitude improvement. For some drugs, may represent limit, while others it be benefit further. To maximize prolong effects, important start early adjust dosage treatment. Other strategies involve combinations with other cholinergic such muscarinic or nicotinic agonists. A class which developed m1 However, their use still limited by side effects. The increased knowledge recognition beta-amyloid molecule central focus pathology strongly stimulated research hope finding ways influencing its processing deposition. At point, no product line development reached trial level. approaches related preventive neuroprotective interventions (estrogens, anti-oxidants anti-inflammatories). In conclusion, given relatively short field, encouraging.